Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s D&A?
- Cullinan Therapeutics, Inc. (CGEM) reported D&A of $79K in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s D&A changed year-over-year?
- Cullinan Therapeutics, Inc.'s D&A increased by 2.6% year-over-year, from $77K to $79K.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s D&A has grown at a 55.6% compound annual growth rate (CAGR), from $53K to $311K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Cullinan Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude